tetano
Editor, Senior Moderator
Euro Surveill. 2020 Mar;25(11). doi: 10.2807/1560-7917.ES.2020.25.11.2000266.
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.
Haveri A[SUP]1[/SUP], Smura T[SUP]2[/SUP], Kuivanen S[SUP]2[/SUP], ?sterlund P[SUP]1[/SUP], Hepojoki J[SUP]3,[/SUP][SUP]2[/SUP], Ikonen N[SUP]1[/SUP], Pitk?paasi M[SUP]1[/SUP], Blomqvist S[SUP]1[/SUP], R?nkk? E[SUP]1[/SUP], Kantele A[SUP]4[/SUP], Strandin T[SUP]2[/SUP], Kallio-Kokko H[SUP]5[/SUP], Mannonen L[SUP]5[/SUP], Lappalainen M[SUP]5[/SUP], Broas M[SUP]6[/SUP], Jiang M[SUP]7,[/SUP][SUP]1[/SUP], Siira L[SUP]1[/SUP], Salminen M[SUP]1[/SUP], Puumalainen T[SUP]1[/SUP], Sane J[SUP]1[/SUP], Melin M[SUP]1[/SUP], Vapalahti O[SUP]5,[/SUP][SUP]2[/SUP], Savolainen-Kopra C[SUP]1[/SUP].
Author information
Abstract
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.
KEYWORDS:
COVID-19; SARS-CoV-2; antibodies; coronavirus; humoral immunity; immunofluorescence assay; microneutralisation test; western blotting; whole-genome sequencing
PMID:32209163DOI:10.2807/1560-7917.ES.2020.25.11.2000266
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.
Haveri A[SUP]1[/SUP], Smura T[SUP]2[/SUP], Kuivanen S[SUP]2[/SUP], ?sterlund P[SUP]1[/SUP], Hepojoki J[SUP]3,[/SUP][SUP]2[/SUP], Ikonen N[SUP]1[/SUP], Pitk?paasi M[SUP]1[/SUP], Blomqvist S[SUP]1[/SUP], R?nkk? E[SUP]1[/SUP], Kantele A[SUP]4[/SUP], Strandin T[SUP]2[/SUP], Kallio-Kokko H[SUP]5[/SUP], Mannonen L[SUP]5[/SUP], Lappalainen M[SUP]5[/SUP], Broas M[SUP]6[/SUP], Jiang M[SUP]7,[/SUP][SUP]1[/SUP], Siira L[SUP]1[/SUP], Salminen M[SUP]1[/SUP], Puumalainen T[SUP]1[/SUP], Sane J[SUP]1[/SUP], Melin M[SUP]1[/SUP], Vapalahti O[SUP]5,[/SUP][SUP]2[/SUP], Savolainen-Kopra C[SUP]1[/SUP].
Author information
Abstract
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.
KEYWORDS:
COVID-19; SARS-CoV-2; antibodies; coronavirus; humoral immunity; immunofluorescence assay; microneutralisation test; western blotting; whole-genome sequencing
PMID:32209163DOI:10.2807/1560-7917.ES.2020.25.11.2000266